Matti Vänskä

Dr. Matti Vänskä

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2011 in Haematologica
Verified
Journal Article
Closed access
MVMatti Vänskä
Matti Vänskä
IKI. Koivula
I. Koivula
SHS. Hamalainen
S. Hamalainen
KPK. Pulkki
K. Pulkki
TNT. Nousiainen
T. Nousiainen
AJAuni Juutilainen
Auni Juutilainen
We evaluated pentraxin 3 as a marker for complications of neutropenic fever in 100 hematologic patients receiving intensive chemotherapy. Pentraxin 3 and C-reactive protein were measured at fever onset and then daily to day 3. Bacteremia was observed in 19 patients and septic shock in 5 patients (three deaths). In comparison to C-reactive protein, pentraxin 3 achieved its maximum more rapidly. Pentraxin 3 correlated not only with the same day C-reactive protein but also with the next day C-reactive protein. High pentraxin 3 on day 0 was associated with the development of septic shock (P=0.009) and bacteremia (P=0.046). The non-survivors had constantly high pentraxin 3 levels. To conclude, pentraxin 3 is an early predictor of complications in hematologic patients with neutropenic fever. High level of pentraxin 3 predicts septic shock and bacteremia already at the onset of febrile neutropenia. (ClinicalTrials.gov Identifier: NCT00781040.).

17 August 2012 in Cytokine
Verified
Journal Article
Closed access
MVMatti Vänskä
Matti Vänskä
IKIrma Koivula
Irma Koivula
EJEsa Jantunen
Esa Jantunen
SHSari Hämäläinen
Sari Hämäläinen
APAnna-Kaisa Purhonen
Anna-Kaisa Purhonen
AJAuni Juutilainen
Auni Juutilainen

22 January 2015 in Infectious Diseases
Verified
Journal Article
Closed access
PDF file
APAnna-Kaisa Purhonen
Anna-Kaisa Purhonen
AJAuni Juutilainen
Auni Juutilainen
MVMatti Vänskä
Matti Vänskä
MLMaija Lehtikangas
Maija Lehtikangas
PLPäivi Lakkisto
Päivi Lakkisto
KPKari Pulkki
Kari Pulkki
Neutropenic fever is common in patients receiving intensive chemotherapy for hematological malignancies. The clinical course may be aggravated by infectious complications like severe sepsis, septic shock or even death. We prospectively studied 100 patients with neutropenic fever and evaluated human plasma cell-free DNA (cfDNA) during the first 3 days after the onset of fever as a prognostic biomarker for complicated clinical course, defined as sepsis or septic shock. Complicated course was observed in 21 patients (21%). There were no significant differences in cfDNA levels between the patients with or without complications on any study day when all the patients were analyzed as one group. In subgroups according to hematological malignancy, patients with acute myeloid leukemia (AML) had lower cfDNA levels than patients with lymphoma. Among AML patients d0 cfDNA/leukocyte ratio and among lymphoma patients d0 cfDNA was associated with subsequent development of sepsis or septic shock. cfDNA deserves further studies in hematological patients with sepsis.

25 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMArtturi Mäkinen
Artturi Mäkinen
ANAtte Nikkilä
Atte Nikkilä
THTeppo Haapaniemi
Teppo Haapaniemi
LOLaura Oksa
Laura Oksa
JMJuha Mehtonen
Juha Mehtonen
OLOlli Lohi
Olli Lohi
The oncofetal protein insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) belongs to a family of RNA-binding proteins involved in localization, stability, and translational regulation of target RNAs. IGF2BP3 is used as a diagnostic and prognostic marker in several malignancies. Although the prognosis of pediatric B-cell acute lymphoblastic leukemia (B-ALL) has improved, a subgroup of patients exhibits high-risk features and suffer from disease recurrence. We sought to identify additional biomarkers to improve diagnostics, and we assessed expression of IGF2BP3 in a population-based pediatric cohort of B-ALL using a tissue microarray platform. The majority of pediatric B-ALL cases were positive for IGF2BP3 immunohistochemistry and were associated with an increased proliferative phenotype and activated STAT5 signaling pathway. Two large gene expression data sets were probed for the expression of IGF2BP3—the highest levels were seen among the B-cell lymphomas of a germinal center origin and well-established (KMT2A-rearranged and ETV6-RUNX1) and novel subtypes of B-ALL (e.g., NUTM1 and ETV6-RUNX1-like). A high mRNA for IGF2BP3 was associated with a proliferative “metagene” signature and a high expression of CDK6 in B-ALL. A low expression portended inferior survival in a high-risk cohort of pediatric B-ALL. Overall, our results show that IGF2BP3 shows subtype-specificity in expression and provides prognostic utility in high-risk B-ALL.

15 June 2011 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AJAuni Juutilainen
Auni Juutilainen
MVMatti Vänskä
Matti Vänskä
KPKari Pulkki
Kari Pulkki
SHSari Hämäläinen
Sari Hämäläinen
TNTapio Nousiainen
Tapio Nousiainen
IKIrma Koivula
Irma Koivula

5 January 2018 in Infectious Diseases
Verified
Journal Article
Closed access
RRRosa Rönkkö
Rosa Rönkkö
AJAuni Juutilainen
Auni Juutilainen
IKIrma Koivula
Irma Koivula
MVMatti Vänskä
Matti Vänskä
TNTapio Nousiainen
Tapio Nousiainen
SHSari Hämäläinen
Sari Hämäläinen
Background: The aim of the study was to explore the incidence, microbiological etiology and outcome of febrile neutropenia among adult hematological patients following autologous stem cell transplantation (ASCT). Methods: The study population consisted of patients who received ASCT between 1 December 2006 and 30 November 2012. The epidemiology was compared to a retrospective series covering eleven previous years at the same institution. Non-Hodgkin lymphoma (NHL) patients, who had been identified as a risk group in the retrospective study, received ciprofloxacin prophylaxis from January 2008. Results: Altogether, 142 out of 178 of the included patients (80%) developed febrile neutropenia. The blood cultures were positive in 24 cases (17%). Of all bacteremia’s, 88% were caused by Gram-positive and 12% by Gram-negative bacteria. The number of Gram-negative bacteremia were significantly lower in the prospective study compared to the retrospective study (3/142, 2.1% vs. 23/265, 8.7%, p = .01). Pseudomonas aeruginosa was prevalent in the retrospective series but not discovered in the present series. Enterococcus faecium was found more frequently in the prospective study (6/142, 4.2 vs. 2/265, 0.8%, p = .02). The infectious mortality among patients with febrile neutropenia was 4/142 (2.8%) in the present series and 9/265 (3.4%) in those who received ASCT in 1996–2006. Conclusion: Most patients who received ASCT developed febrile neutropenia and a minority had bacteraemia. In comparison to the earlier time period, the incidence of Gram-negative bacteraemias decreased, probably due to ciprofloxacin prophylaxis in NHL patients, but simultaneously the incidence of Enterococcus bacteraemias increased. Infectious mortality during febrile neutropenia was low in both series.